Trajectories of suicidal ideation during rTMS for treatment-resistant depression
- PMID: 38788857
- DOI: 10.1016/j.jad.2024.05.109
Trajectories of suicidal ideation during rTMS for treatment-resistant depression
Abstract
Background: rTMS is a safe and effective intervention for treatment-resistant depression (TRD). However, there is limited data on its specific impact on suicidal ideation (SI), and the trajectory of SI over the treatment course.
Objective: This open-label clinical trial investigated SI outcomes and trajectories in patients with TRD receiving low-frequency rTMS (LFR) to the right dorsolateral prefrontal cortex (DLPFC; N = 55).
Methods: A latent class mixed-effect model was used to identify response trajectories for SI as well as core mood symptoms. Logistic regression analyses investigated risk factors associated with identified trajectories.
Results: For each symptom domain, we identified two distinct trajectories during LFR, one tracking improvement (SI: n = 35, 60 %; mood: n = 29, 53 %) and the other tracking no improvement (SI: n = 20, 40 %; mood: n = 26, 47 %). Male sex, higher baseline anxiety, and higher baseline SI were risk factors for no improvement of SI; while higher baseline anxiety and benzodiazepine use were risk factors for no improvement of mood. Mediation analyses showed that anxiety was a risk factor for no improvement of SI and mood independent of benzodiazepine treatment.
Conclusions: This is the first study to investigate trajectories of response to LFR to the right DLPFC. SI and mood improved with LFR in most patients but the severity of anxiety symptoms was a factor of poor prognosis for both. Nuanced characterization of SI response to rTMS may lead to critical insights for individualized targeting strategies.
Keywords: Low frequency rTMS; Right DLPFC; Suicidal ideation; Symptom trajectories; Treatment-resistant depression.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no financial interests relative to this work. FVR receives research support from CIHR, Brain Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and in-kind equipment support for this investigator-initiated trial from MagVenture. He has received honoraria for participation in the advisory board for Janssen.
Similar articles
-
Comparisons of Accelerated Continuous and Intermittent Theta Burst Stimulation for Treatment-Resistant Depression and Suicidal Ideation.Biol Psychiatry. 2024 Jul 1;96(1):26-33. doi: 10.1016/j.biopsych.2023.12.013. Epub 2023 Dec 22. Biol Psychiatry. 2024. PMID: 38142717 Clinical Trial.
-
An Open-label Trial of Adjuvant High-frequency Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Treating Suicidal Ideation in Adolescents and Adults With Depression.J ECT. 2021 Jun 1;37(2):140-146. doi: 10.1097/YCT.0000000000000739. J ECT. 2021. PMID: 33337649 Clinical Trial.
-
Depressive symptom trajectories associated with standard and accelerated rTMS.Brain Stimul. 2020 May-Jun;13(3):850-857. doi: 10.1016/j.brs.2020.02.021. Epub 2020 Feb 21. Brain Stimul. 2020. PMID: 32289716 Clinical Trial.
-
Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression.J Clin Psychiatry. 2018 May/Jun;79(3):17m11692. doi: 10.4088/JCP.17m11692. J Clin Psychiatry. 2018. PMID: 29701939
-
[Repetitive transcranial magnetic stimulation in major depression: response factor].Encephale. 2012 Sep;38(4):360-8. doi: 10.1016/j.encep.2011.08.004. Epub 2011 Oct 11. Encephale. 2012. PMID: 22980479 Review. French.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical